MOUNTAIN VIEW, Calif., June 26 /PRNewswire/ -- The Vaccines and Related
Biological Products Advisory Committee of the U.S. Food and Drug
Administration (FDA) is scheduled to evaluate FluMist(TM), Aviron's
investigational intranasal influenza vaccine, at their July 26-27 meeting,
according to today's Federal Register.
On October 31, 2000, Aviron submitted a Biologics License Application to
the FDA seeking licensure of FluMist(TM) to prevent influenza in healthy
children and healthy adults.
Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.
To receive an index and copies of recent press releases, call Aviron's
News-On-Call toll-free fax service, 800-758-5804, extension 114000.
Additional information about the company can be located at
http://www.aviron.com .
SOURCE Aviron
 back to top
Related links:
http://www.aviron.com
Company News On-Call:
http://www.prnewswire.com/comp/114000.html or fax,
800-758-5804, ext. 114000
CONTACT:
media or investors, John Bluth, 650-919-3716,
or Asha Jennings, 650-919-1429, both of Aviron; or media, Ben
Butkus of Fleishman-Hillard, 212-453-2000, for Aviron; or
investors Fred Kurland of Aviron, 650-919-6666
|
